Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
gemcitabine
i
Other names:
LY-188011, dFdC, LY 188011, LY188011
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(181)
News
Trials
Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor
Related drugs:
‹
cisplatin (330)
temozolomide (114)
cytarabine (99)
oxaliplatin (57)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
mitomycin (10)
temozolomide gel (7)
nedaplatin (6)
fludarabine IV (6)
nelarabine (5)
bleomycin (4)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
FF-10502 (2)
fotemustine (2)
streptozocin (2)
fludarabine oral (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
gemcitabine-releasing intravesical system (1)
mitomycin urothelial gel (1)
melphalan hepatic delivery system (1)
INT230-6 (1)
Ganfule (0)
liposomal cisplatin (0)
MKC-1106 (0)
miriplatin (0)
zinostatin (0)
pegylated liposomal mitomycin-c prodrug (0)
mercaptopurine oral suspension (0)
gemcitabine with RenovoCath (0)
cytarabine ocfosfate (0)
TG6002 (0)
dimesna (0)
mitomycin intravesicular (0)
SY-2101 (0)
captisol-enabled melphalan (0)
CO 1.01 (0)
D07001 (0)
TAS-118 (0)
PRV211 (0)
LP-100 (0)
PCS3117 (0)
PTX-200 (0)
cisplatin (330)
temozolomide (114)
cytarabine (99)
oxaliplatin (57)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
mitomycin (10)
temozolomide gel (7)
nedaplatin (6)
fludarabine IV (6)
nelarabine (5)
bleomycin (4)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
FF-10502 (2)
fotemustine (2)
streptozocin (2)
fludarabine oral (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
gemcitabine-releasing intravesical system (1)
mitomycin urothelial gel (1)
melphalan hepatic delivery system (1)
INT230-6 (1)
Ganfule (0)
liposomal cisplatin (0)
MKC-1106 (0)
miriplatin (0)
zinostatin (0)
pegylated liposomal mitomycin-c prodrug (0)
mercaptopurine oral suspension (0)
gemcitabine with RenovoCath (0)
cytarabine ocfosfate (0)
TG6002 (0)
dimesna (0)
mitomycin intravesicular (0)
SY-2101 (0)
captisol-enabled melphalan (0)
CO 1.01 (0)
D07001 (0)
TAS-118 (0)
PRV211 (0)
LP-100 (0)
PCS3117 (0)
PTX-200 (0)
›
Associations
(181)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A1
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A1
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Sarcoma
No biomarker
Sarcoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
No biomarker
Sarcoma
No biomarker
Sarcoma
gemcitabine + dacarbazine
Sensitive: A2 - Guideline
gemcitabine + dacarbazine
Sensitive
:
A2
gemcitabine + dacarbazine
Sensitive: A2 - Guideline
gemcitabine + dacarbazine
Sensitive
:
A2
No biomarker
Sarcoma
No biomarker
Sarcoma
gemcitabine + vinorelbine tartrate
Sensitive: A2 - Guideline
gemcitabine + vinorelbine tartrate
Sensitive
:
A2
gemcitabine + vinorelbine tartrate
Sensitive: A2 - Guideline
gemcitabine + vinorelbine tartrate
Sensitive
:
A2
No biomarker
Sarcoma
No biomarker
Sarcoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + capecitabine
Sensitive: A2 - Guideline
gemcitabine + capecitabine
Sensitive
:
A2
gemcitabine + capecitabine
Sensitive: A2 - Guideline
gemcitabine + capecitabine
Sensitive
:
A2
BRCA1 mutation
Pancreatic Adenocarcinoma
BRCA1 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
BRCA2 mutation
Pancreatic Adenocarcinoma
BRCA2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
PALB2 mutation
Pancreatic Adenocarcinoma
PALB2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
No biomarker
Thymic Carcinoma
No biomarker
Thymic Carcinoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Thymoma
No biomarker
Thymoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
gemcitabine + paclitaxel
Sensitive: A2 - Guideline
gemcitabine + paclitaxel
Sensitive
:
A2
gemcitabine + paclitaxel
Sensitive: A2 - Guideline
gemcitabine + paclitaxel
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
gemcitabine + paclitaxel
Sensitive: A2 - Guideline
gemcitabine + paclitaxel
Sensitive
:
A2
gemcitabine + paclitaxel
Sensitive: A2 - Guideline
gemcitabine + paclitaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
gemcitabine + paclitaxel + oxaliplatin
Sensitive: A2 - Guideline
gemcitabine + paclitaxel + oxaliplatin
Sensitive
:
A2
gemcitabine + paclitaxel + oxaliplatin
Sensitive: A2 - Guideline
gemcitabine + paclitaxel + oxaliplatin
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Nasopharyngeal Carcinoma
No biomarker
Nasopharyngeal Carcinoma
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
No biomarker
Nasopharyngeal Carcinoma
No biomarker
Nasopharyngeal Carcinoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Bladder Cancer
No biomarker
Bladder Cancer
gemcitabine + ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
gemcitabine + ifosfamide + pegylated liposomal doxorubicin
Sensitive
:
A2
gemcitabine + ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
gemcitabine + ifosfamide + pegylated liposomal doxorubicin
Sensitive
:
A2
No biomarker
Bladder Cancer
No biomarker
Bladder Cancer
gemcitabine + paclitaxel
Sensitive: A2 - Guideline
gemcitabine + paclitaxel
Sensitive
:
A2
gemcitabine + paclitaxel
Sensitive: A2 - Guideline
gemcitabine + paclitaxel
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login